Loading clinical trials...
Loading clinical trials...
Adoptive Transfer of NY-ESO-1 TCR Engineered Peripheral Blood Mononuclear Cells (PBMC) and Peripheral Blood Stem Cells (PBSC) After a High Dose Melphalan Conditioning Regimen, With Administration of Interleukin-2, in Patients With Multiple Myeloma
Conditions
Interventions
18F-FHBG
Aldesleukin
+9 more
Locations
1
United States
UCLA / Jonsson Comprehensive Cancer Center
Los Angeles, California, United States
Start Date
July 10, 2018
Primary Completion Date
June 25, 2019
Completion Date
June 25, 2019
Last Updated
July 24, 2020
NCT05312255
NCT04508790
NCT04640779
NCT05288062
NCT02765854
NCT05191472
Lead Sponsor
Jonsson Comprehensive Cancer Center
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions